Source: BJU international [BJU Int] 2010 Dec; Vol. 106 (11), pp. 1643-7.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print Cited Medium: Internet ISSN: 1464-410X

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Authors : Aragon-Ching JB; Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.; Jain L

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Bone Neoplasms/Bone Neoplasms/Bone Neoplasms/*drug therapy

Source: BJU international [BJU Int] 2009 Jun; Vol. 103 (12), pp. 1636-40. Date of Electronic Publication: 2009 Jan 09.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.

Authors : Benedict A; United BioSource Corporation, London, UK.; Figlin RA

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*economics ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: BJU international [BJU Int] 2011 Sep; Vol. 108 (5), pp. 665-72. Date of Electronic Publication: 2011 Jan 25.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Authors : Iacovelli R; Medical Oncology Department, Institut Gustave Roussy, Villejuif, France.; Lanoy E

Subjects: Tumor Burden*/Tumor Burden*/Tumor Burden*/physiology; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*pathology ; Kidney Neoplasms/Kidney Neoplasms/Kidney Neoplasms/*pathology

Source: BJU international [BJU Int] 2012 Dec; Vol. 110 (11), pp. 1747-53. Date of Electronic Publication: 2012 Oct 26.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Authors : Masini C; Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy. ; Sabbatini R

Subjects: Renal Dialysis*; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*administration & dosage ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*administration & dosage

Source: BJU international [BJU Int] 2012 Sep; Vol. 110 (5), pp. 692-8. Date of Electronic Publication: 2012 Feb 24.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Editorial & Opinion

Sorafenib rechalenge in metastatic renal cell carcinoma.

Authors : Porta C; Paglino C; Imarisio I

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: BJU international [BJU Int] 2012 Sep; Vol. 110 (6 Pt B), pp. E235. Date of Electronic Publication: 2012 Feb 14.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sorafenib rechallenge in patients with metastatic renal cell carcinoma.

Authors : Nozawa M; Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. ; Yamamoto Y

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: BJU international [BJU Int] 2012 Sep; Vol. 110 (6 Pt B), pp. E228-34. Date of Electronic Publication: 2012 Feb 14.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Authors : Yuasa T; Department of Urology , Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan. ; Tsuchiya N

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Indoles/Indoles/Indoles/*therapeutic use

Source: BJU international [BJU Int] 2012 May; Vol. 109 (9), pp. 1349-54. Date of Electronic Publication: 2011 Aug 25.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Authors : Mancuso A; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. ; Di Paola ED

Subjects: Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*administration & dosage ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Kidney Neoplasms/Kidney Neoplasms/Kidney Neoplasms/*drug therapy

Source: BJU international [BJU Int] 2012 Jan; Vol. 109 (2), pp. 200-6.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print Cited Medium: Internet ISSN: 1464-410X

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.

Authors : Naito S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ; Tsukamoto T

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use ; Benzenesulfonates/Benzenesulfonates/Benzenesulfonates/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

Source: BJU international [BJU Int] 2011 Dec; Vol. 108 (11), pp. 1813-9. Date of Electronic Publication: 2011 Apr 11.Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.

Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.

Sorafenib rechalenge in metastatic renal cell carcinoma.

Sorafenib rechallenge in patients with metastatic renal cell carcinoma.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.

اتصل بنا

اتبع